STAT
JUNE 17, 2024
The Food and Drug Administration on Monday approved Merck’s new pneumococcal vaccine for adults 18 and older. The vaccine, which will be sold under the name Capvaxive, is designed to protect against pneumococcal pneumonia, which hospitalizes about 150,000 adults in the United States every year and kills about 1 in 20 who develop it, according to the National Foundation for Infectious Diseases.
PharmaVoice
JUNE 17, 2024
While AI has exploded in popularity across various industries, including pharma and life sciences, many companies have launched models that haven't delivered on their full potential.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
JUNE 17, 2024
Bird flu snapshot: This is the first in a series of regular updates on H5N1 avian flu that STAT is publishing on Monday mornings. To read future updates you can also subscribe to STAT’s Morning Rounds newsletter. Seth Berkley, the former head of Gavi, the Vaccine Alliance, gave voice last week to a point of view STAT has been hearing for a while about the U.S. response to the H5N1 bird flu outbreak in dairy cows.
PharmaVoice
JUNE 17, 2024
How Roche is finding better ways to diagnose brain conditions like Alzheimer’s and Parkinson’s disease.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
JUNE 17, 2024
WASHINGTON — E-cigarettes were about as effective at helping people quit smoking as the gold-standard pharmaceutical drug, varenicline, according to a clinical trial published Monday in JAMA Internal Medicine. The trial randomized 458 people who smoked daily and wanted to quit to receive either a nicotine-containing e-cigarette and placebo tablets, varenicline and an e-cigarette without nicotine, or a placebo tablet and a nicotine-free e-cigarette for 12 weeks.
BioPharma Dive
JUNE 17, 2024
One expert described trial results presented at EULAR last week as “unprecedented.” But reports of relapses in some patients drew questions about the therapies’ ultimate potential.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
Pharmaceutical Technology
JUNE 17, 2024
Novavax has sought US FDA approval for an updated JN.1 version of its Covid-19 vaccine, NVX-CoV2705, for individuals aged 12 years and above.
STAT
JUNE 17, 2024
United States Surgeon General Vivek Murthy wants to add a warning label on social media. “It is time to require a surgeon general’s warning label on social media platforms, stating that social media is associated with significant mental health harms for adolescents,” he wrote in an op-ed published on Monday in the New York Times, calling on Congress to take action to add the warning, which would be along the lines of the ones issued against tobacco and alcohol consumption.
EMCrit Project
JUNE 17, 2024
introduction Bilevel Sequence Intubation (BSI) refers to initiation of noninvasive bilevel positive pressure ventilation with a backup rate prior to intubation (either using a BiPAP machine or a full-featured mechanical ventilator). BSI is distinct from traditional rapid sequence intubation (RSI), since BSI involves the delivery of machine-initiated, pressure-controlled breaths following administration of sedation and paralytics. […] EMCrit Project by Josh Farkas.
STAT
JUNE 17, 2024
The former CEO of Stimwave, a company that sold pain-relief devices with dummy pieces of plastic, was sentenced Monday by a New York judge to six years in prison. Stimwave sold nerve stimulation devices to combat pain. Under CEO Laura Perryman’s leadership, the company warped the design of their devices to earn more reimbursement money from insurers, resulting in unnecessary plastic parts that allowed doctors to claim around $18,000 more than they previously could.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
pharmaphorum
JUNE 17, 2024
Discover how leading tech giants such as Amazon, Google, Apple, and Microsoft are shaping the future of public health diagnostics through MedTech innovations. Explore the potential impact on healthcare and stay informed on the latest developments.
STAT
JUNE 17, 2024
A late-night Flomax commercial is sometimes all it takes for me to start spinning in a cycle of anxiety. If I don’t need Flomax to help me pee better, then I imagine I probably need a screening for prostate cancer. I’m a hypochondriac. I’m also a health care executive with insight into how the U.S. health care system works — and doesn’t work — which may contribute to my hyper focus on health.
pharmaphorum
JUNE 17, 2024
Explore the impact and influence of trending health information, like Ozempic and the Eddy Effect on platforms like TikTok, through conversation data analysis. Learn more about these trends and their implications.
STAT
JUNE 17, 2024
In a bid to prevent the patent system from being abused, the U.S. Patent and Trademark Office has proposed a new rule designed to stem the use of so-called patent thickets , which are wielded by pharmaceutical companies to delay the arrival of lower-cost generic medicines in the marketplace. Essentially, thickets are collections of numerous patents that add only incremental changes to a drug and, therefore, produce little to no additional benefit to patients.
Drug Patent Watch
JUNE 17, 2024
The article “The devil is in the divisional: an analysis of divisional patents, deadlines, declarations and suggestions for future practice” by Mieke Filler provides a comprehensive analysis of the strategic use of divisional patents in the pharmaceutical sector to delay generic and biosimilar market entry.
STAT
JUNE 17, 2024
You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow of money in medicine. Sign up to get it in your inbox every Monday. Putting your money where your mouth is Large companies rarely switch health insurance vendors. It’s a pain in the butt for everyone involved, even if the current setup is a raw deal.
Express Pharma
JUNE 17, 2024
The recent results from the ECHO Phase III trial showed AstraZeneca’s CALQUENCE (acalabrutinib) in combination with bendamustine and rituximab demonstrated an improvement in progression-free survival (PFS) and showed a favourable trend in overall survival (OS) compared to standard-of-care chemoimmunotherapy (bendamustine plus rituximab) in previously untreated patients with mantle cell lymphoma (MCL).
STAT
JUNE 17, 2024
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello! Today, we talk about the uptick in physicians using ctDNA to determine if resected cancers are truly gone, we see the FDA offering new guidelines for Covid-19 vaccines, and more.
pharmaphorum
JUNE 17, 2024
Learn how to upscale your brand strategy with new and innovative ways of planning. Discover effective brand planning strategies to take your brand to the next level.
STAT
JUNE 17, 2024
The California Public Employees’ Retirement System is making a drastic change to one of its major health insurance plans for the state’s employees and retirees: It’s switching health insurance carriers, and forcing its new partners to earn their fees instead of automatically getting them. The new contract could serve as a model for other large employers that are fully on the hook for their workers’ health care costs and want their insurance companies to do more to kee
Drug Patent Watch
JUNE 17, 2024
Pharmaceutical companies employ various strategies to extend the commercial life and patent protection of successful drugs. Here are some key approaches with examples: New Formulations One common strategy is to develop and patent new formulations of the existing drug compound to provide benefits like reduced dosing frequency, easier administration, improved bioavailability, or reduced side effects.
BioPharma Dive
JUNE 17, 2024
One biotech executive called the Supreme Court’s decision a “very important win” for the industry, although new challenges to the FDA’s regulation of the drug could still be forthcoming.
Express Pharma
JUNE 17, 2024
Ascentage Pharma, a global biopharmaceutical company engaged in developing therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, recently announced the signing of an option agreement with Takeda to enter into an exclusive licence agreement for olverembatinib, an oral, BCR-ABL tyrosine kinase inhibitor (TKI), which is currently in development for chronic myeloid leukaemia (CML) and other haematological cancers.
Drug Patent Watch
JUNE 17, 2024
A recent whitepaper by Hermann Mucke summarizes the steps to performing an FTO for drug repurposing: Overview An FtO analysis determines if a new product or process can proceed without infringing third-party intellectual property (IP) rights, especially patents. It is crucial for drug repurposing projects involving known compounds that may still be patent-protected.
Express Pharma
JUNE 17, 2024
Merck has announced that the U.S. Food and Drug Administration (FDA) has approved CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine) for, active immunisation for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F and 35B in individuals 18 years of age and older.
pharmaphorum
JUNE 17, 2024
Two executives at telehealth startup Done Global have been arrested and face allegations of fraud involving the distribution of medicines for ADHD
Pharma Times
JUNE 17, 2024
Cancer was estimated to be responsible for more than 18 million cases worldwide in 2020
Express Pharma
JUNE 17, 2024
Global pharma major Lupin (Lupin) announced the appointment of Abdelaziz Toumi (Abdel) as the Chief Executive Officer of its newly formed subsidiary, Lupin Manufacturing Solutions (LMS). LMS is engaged in the development, manufacture and sale of Active Pharmaceutical Ingredients and is starting to build its Contract Development and Manufacturing Operations (CDMO) business.
pharmaphorum
JUNE 17, 2024
Sanofi and Innate Pharma NK cell engager therapy SAR443579 shows promising efficacy in AML patients in a phase 1/2 trial reported at EHA.
BioPharma Dive
JUNE 17, 2024
The new company, Spur Therapeutics, is getting another $50 million from Syncona to support its broadened pipeline, which targets Parkinson’s disease as well as heart conditions.
Pharmaceutical Technology
JUNE 17, 2024
TC-110 is under clinical development by Adaptimmune Therapeutics and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia).
pharmaphorum
JUNE 17, 2024
Stanford Medicine study finds risk of secondary cancers with CAR-T therapies is low and likely unrelated to the treatments themselves
Pharmaceutical Technology
JUNE 17, 2024
Equecabtagene autoleucel is under clinical development by Nanjing IASO Biotherapeutics and currently in Phase II for Refractory Multiple Myeloma.
pharmaphorum
JUNE 17, 2024
Takeda’s experimental epilepsy drug soticlestat has failed phase 3 trials in Dravet syndrome and Lennox-Gastaut syndrome
Pharmaceutical Technology
JUNE 17, 2024
Equecabtagene autoleucel is under clinical development by Nanjing IASO Biotherapeutics and currently in Phase II for Relapsed Multiple Myeloma.
Expert insights. Personalized for you.
363 
Let's personalize your content